JAMA Cardiology publishes findings from Amgen's 4-year study of Repatha
The results from Amgen’s four-year follow up OSLER-1 study on Repatha, which is so far the longest PCSK9 inhibitor clinical trial, were recently published in JAMA Cardiology. Read More »